In 2022, the American Diabetes Association (ADA) updated their guidelines, recommending GLP-1 RA and SGLT-2i as first-line therapy for T2DM, especially for individuals with CVD, CKD, and HF [11]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.